ArticleFrontiers in oncology2023

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC.

Michael Cekay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.